In this episode, Joe Moore interviews Dr. Rachel Yehuda: neuroscientist, researcher, Professor and Vice Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai, and Director of Mental Health at the James J. Peters VA Medical Center. Dr. Yehuda talks about the importance and complications of research trials: the difficulty researchers have in remaining neutral; how protocols have an arbitrary beginning and end that may not make sense to the participant; how the process of getting funding for one’s own clinical trial begins with creating a specific protocol; and how, while it can often feel like therapy for participants, the purpose of these trials is often more for researchers to learn from participants how to better run the trials themselves. And she discusses her background and path to psychedelic research, why knowing the pharmacology of a compound doesn’t explain enough, what she thinks the next few years of psychedelic neuroscience looks like, how to work with big corporations who may seem like they’re only in it for the money, and how we need a science to predict and analyze who will or won’t respond to a particular treatment (and why).

The post PT270 – Dr. Rachel Yehuda – Research Trials and The Future of Psychedelic Neuroscience appeared first on Psychedelics Today.

Previous articleComplete Results from Red Light Oregon Market Research in Oregon Show Microdosing Services Market Size per Annum Estimated at a Billion USD
Next articleMindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board